Henry Schein, Inc. (HSIC)
Henry Schein is a global distributor of dental and medical supplies, acting as the essential middleman that keeps clinics stocked with everything from drills to gloves.
Is Henry Schein, Inc. a good stock for a UK beginner?
The honest version: Henry Schein is a global distributor of dental and medical supplies, acting as the essential middleman that keeps clinics stocked with everything from drills to gloves.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Significant market share gains in the global medical supply sector.
Long-term decline in profit margins due to pricing pressure.
What does Henry Schein, Inc. do?
Think of Henry Schein as the 'Amazon' for dentists and doctors; they provide the vast array of equipment, software, and supplies needed to run a healthcare practice. Buying these goods in bulk and selling them on to thousands of independent clinics is the core business, alongside technology services that help those clinics manage their bookings and records. Much rides on how well they hold costs down while navigating the steady but slow growth of the healthcare supply market.
On our factor screen it looks strongest on momentum and value, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 6% over the year
- !Thin profits - turns only about 3% of sales into profit
- Momentum screens high (73/100)
- Essential service provider with a wide customer base
- Lower volatility compared to the broader market
- Strong position in the dental supply niche
- Quality screens low (31/100)
- Income screens low (16/100)
- Dependence on the financial health of independent dental practices
- Potential for supply chain disruptions
- Pressure on prices from large hospital groups and competitors
What do Henry Schein, Inc.'s numbers mean?
How much money does Henry Schein, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Henry Schein, Inc. pay a dividend?
No - Henry Schein, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Henry Schein, Inc. report earnings, and how did recent quarters go?
Henry Schein, Inc. is next scheduled to report on about 2026-08-04 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-05 | $1.22 | $1.32 | Beat +8% |
| 2026-02-24 | $1.29 | $1.34 | Beat +3% |
| 2025-11-04 | $1.28 | $1.38 | Beat +8% |
| 2025-08-05 | $1.19 | $1.10 | Missed -8% |
| 2025-05-05 | $1.11 | $1.15 | Beat +4% |
| 2025-02-25 | $1.21 | $1.19 | Missed -2% |
Across the last 6 quarters here, Henry Schein, Inc. came in ahead of what analysts expected 4 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Henry Schein, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Henry Schein, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Essential service provider with a wide customer base
- Lower volatility compared to the broader market
- Strong position in the dental supply niche
- Very thin profit margins leave little room for error
- No dividend payments for income-focused investors
- Modest growth rates compared to high-tech sectors
- Dependence on the financial health of independent dental practices
- Potential for supply chain disruptions
- Pressure on prices from large hospital groups and competitors
The write-up's own warning lights — if these start happening, the case above changes.
- A significant, sustained drop in net profit margins
- Loss of major supplier contracts or distribution rights
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.